Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-151

what’s the price target on this rationally though? Tom sounds frustrated about share price ceiling - which we all share - but catalysts now are few. No re-rate and it’s bleeding.
Its quoted above as upon regulatory success the payout is “enormous” - But, realistically where does that stand.
I’m a holder with conviction and have a decent packet of shares but im interested in peoples thoughts on price target. Me personally with FDA and EMA TAM my calculation was about 2.50 upon regulatory success + premium on top of sale of asset upon but that’s very rough.

interested in your thoughts.